In addition, a possibility has been raised that GFAP levels could discriminate anti‐AQP4 antibody‐seropositive NMOSD from other demyelinating diseases such as anti‐MOG antibody‐associated diseases.32, 33. This evidence concerns the gene AQP4 and demyelinating disease.